Skip to content

Study · Animal study (in vivo) · mouse · 2006

6 results

Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance.

Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Bistoni G, Rasi G, Velardi A, Fallarino F, Garaci E, Puccetti P

Blood1 Jun 2006Cited by 135 (Europe PMC)

PMID16741252 (opens in a new tab)DOI10.1182/blood-2006-02-004762 (opens in a new tab)PepBankPUB-16741252
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In transfer experiments in mice, thymosin alpha‑1-primed dendritic cells induced T-helper type 1 immunity in a regulatory environment.

    In plain wordsIn mice, dendritic cells primed with thymosin alpha‑1 induced Th1 immunity in a regulatory setting.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1 immunity within a regulatory environment after transfer of primed dendritic cells
    Study

    mousen: not reported in source

    Transfer of dendritic cells in mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In transfer experiments, functionally distinct subsets of differentiated DCs were required for priming and tolerance to a fungal pathogen or alloantigens. In contrast, Talpha1-primed DCs fulfilled multiple requirements, including the induction of T-helper type 1 immunity within a regulatory environment.
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.
  2. 02LabIn vitro (cells)Mechanism

    In human and murine dendritic cells, thymosin alpha‑1 affected T-helper cell priming and tolerance induction.

    In plain wordsIn human and mouse cells, thymosin alpha‑1 changed how dendritic cells prime T-helper cells and induce tolerance.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedT-helper priming and tolerance induction by dendritic cells
    Study

    human, mousen: not reported in source

    Dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Talpha1 affected T-helper cell priming and tolerance induction by human and murine DCs
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.
  3. 03LabIn vitro (cells)Mechanism

    In murine dendritic cells, thymosin alpha‑1 induced IDO expression and function.

    In plain wordsIn mouse cells, thymosin alpha‑1 switched on the IDO enzyme and its activity.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIDO expression and function in murine dendritic cells
    Study

    mousen: not reported in source

    Dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    induced IDO expression and function in the latter cells.
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.
  4. 04LabIn vitro (cells)Mechanism

    In dendritic cells, IDO activation by thymosin alpha‑1 required TLR9 and type I interferon receptor signaling.

    In plain wordsIn cells, thymosin alpha‑1 needed TLR9 and type I interferon receptor signals to activate IDO.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableTLR9 and type I interferon receptor dependence of IDO activation
    Study

    human, mousen: not reported in source

    Dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IDO activation by Talpha1 required TLR9 and type I interferon receptor signaling
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.
  5. 05LabIn vitro (cells)Mechanism

    In dendritic cells, IDO activation by thymosin alpha‑1 resulted in interleukin-10 production.

    In plain wordsIn cells, thymosin alpha‑1 led to production of interleukin-10.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseInterleukin-10 production
    Study

    human, mousen: not reported in source

    Dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IDO activation by Talpha1 required TLR9 and type I interferon receptor signaling and resulted in interleukin-10 production and generation of regulatory T cells.
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.
  6. 06LabIn vitro (cells)Mechanism

    In dendritic cell cultures, IDO activation by thymosin alpha‑1 resulted in generation of regulatory T cells.

    In plain wordsIn cells, thymosin alpha‑1 led to the generation of regulatory T cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRegulatory T cell generation
    Study

    human, mousen: not reported in source

    Dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IDO activation by Talpha1 required TLR9 and type I interferon receptor signaling and resulted in interleukin-10 production and generation of regulatory T cells.
    2 context sentences
    Summary · context
    Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, primes dendritic cells (DCs) for antifungal T-helper type 1 resistance through Toll-like receptor 9 (TLR9) signaling.
    Summary · context
    As TLR9 signaling also activates the immuno-suppressive pathway of tryptophan catabolism via indoleamine 2,3-dioxygenase (IDO), we examined Talpha1 for possible induction of DC-dependent regulatory effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07644897

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Sun Yat-sen Universityn = 5530 May 2023 to est. 30 Sept 2027

Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor

Trial pageClinicalTrials.govUpdated 12 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.